Patent Translate
Powered by EPO and Google
Notice
This translation is machine-generated. It cannot be guaranteed that it is intelligible, accurate,
complete, reliable or fit for specific purposes. Critical decisions, such as commercially relevant or
financial decisions, should not be based on machine-translation output.
CLAIMS EP3235492
1.
Non-therapeutic use of N-acetyl-4-aminophenol (paracetamol), or a mixture of several salts
thereof, for reducing the gastric acid secretion-stimulatory effect of the homeriodictyol (HED) or a
salt thereof or a mixture of HED and one or more salts thereof.
2.
Use according to claim 1, further comprising masking the bitter taste of paracetamol.
3.
Use according to any one of the preceding claims, in a formulation containing HED and / or one or
more salt (s) thereof and paracetamol, the amount of HED and / or salt (s) thereof being sufficient
to promote the gastric acid secretion-stimulating effect of paracetamol and, preferably, is also
sufficient to mask the bitter taste of paracetamol.
27-10-2017
1
4.
Use according to claim 3, wherein in the preparation, the gastric acid secretion-stimulating effect
of paracetamol is reduced by at least 10% by HED and / or the salt (s) thereof in comparison to an
identical preparation without HED and / or salt (s) thereof preferably at least 20%, more preferably
at least 50%, particularly preferably at least 70%, very particularly preferably completely.
5.
Use according to claim 3 or 4, wherein the concentration of HED and / or salt (s) thereof in the
preparation is in the range of 0.000001 to 30 mM, preferably in the range of 0.00001 to 3 mM,
more preferably in the range of 0.0001 to 1 mM, particularly preferably in the range from 0.001 to
0.4 mM.
6.
Use according to any one of claims 3 to 5, wherein the concentration of paracetamol in the
preparation is in the range of 0.001 to 1000 mM, preferably in the range of 0.01 to 800 mM, more
preferably in the range of 0.1 to 750 mM preferably in the range from 1 to 600 mM.
7.
Use according to any one of the preceding claims, preferably according to any one of claims 3 to
6, wherein the ratio of the total concentration of HED and / or salt thereof to the total concentration
of paracetamol is in the range of 1: 100,000 to 1: 1 of 1: 10000 to 1: 2, more preferably in the
range from 1: 5000 to 1:10, particularly preferably in the range from 1: 2000 to 1:20.
8.
Use according to any one of claims 3 to 6 or claim 7 when dependent on any one of claims 3 to 6,
wherein the composition additionally comprises one or more components selected from the group
consisting of eriodictyol, phloretin, hesperetine, 2,4-dihydro-benzoic acid N- Vanillylamide, 5,7-
27-10-2017
2
dihydroxy-4- (4-hydroxyphenyl) -chroman-2-one, 5,7-dihydroxy-4- (4-hydroxy-3-methoxy-phynyl)
5,7-dihydroxy-4- (4-pyridyl) -chroman-2-one, 7,3-dihydroxy-4'-methoxyflavan, lariciresinol and
matairesinol and their respective stereoisomers (diastereomers or Enantiomers).
9.
Use according to any one of the preceding claims wherein the one or more, or all, salts of HED is
selected from the group consisting of sodium, potassium, calcium and ammonium salts.
10.
HED or salt thereof, or mixture of HED and one or more salts thereof or mixture of several salts
thereof for use in a therapeutic method for reducing the gastric acid secretion-stimulating action of
paracetamol.
11.
HED or salt thereof, or mixture of HED and one or more salts thereof or mixture of several salts
thereof for use according to claim 10 in a preparation containing HED and / or one or more salts
thereof and paracetamol wherein the amount of HED and / Salt (s) thereof is sufficient to reduce
the gastric acid secretion-stimulating effect of paracetamol and, preferably, is also sufficient to
mask the bitter taste of paracetamol.
27-10-2017
3